Forest Labs Targeted By Actavis, Say Unconfirmed Media Reports
This article was originally published in The Pink Sheet Daily
Actavis is reported to be in talks to acquire the U.S. specialty firm Forest Labs in a move that would boost Actavis’s branded products business.
You may also be interested in...
Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.
Durable responses have continued to be seen two years after administration of Sarepta’s candidate gene therapy to four boys with Duchenne muscular dystrophy.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.